12.60
-0.09 (-0.71%)
| Previous Close | 12.69 |
| Open | 12.83 |
| Volume | 514,574 |
| Avg. Volume (3M) | 1,244,344 |
| Market Cap | 1,213,008,256 |
| Price / Earnings (Forward) | 16.50 |
| Price / Sales | 7.49 |
| Price / Book | 14.27 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2024 - 11 Nov 2024 |
| Profit Margin | -52.53% |
| Operating Margin (TTM) | -0.65% |
| Diluted EPS (TTM) | -0.750 |
| Quarterly Revenue Growth (YOY) | 613.20% |
| Total Debt/Equity (MRQ) | 51.24% |
| Current Ratio (MRQ) | 2.97 |
| Operating Cash Flow (TTM) | -82.81 M |
| Levered Free Cash Flow (TTM) | -58.92 M |
| Return on Assets (TTM) | -22.14% |
| Return on Equity (TTM) | -78.54% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Avadel Pharmaceuticals plc | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | -3.0 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 1.20 |
|
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Insiders | 4.78% |
| % Held by Institutions | 80.54% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 30.00 (Oppenheimer, 138.10%) | Buy |
| Median | 25.00 (98.41%) | |
| Low | 22.00 (Needham, 74.60%) | Buy |
| Average | 25.67 (103.73%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 13.17 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 13 Nov 2024 | 25.00 (98.41%) | Buy | 12.02 |
| 31 Oct 2024 | 27.00 (114.29%) | Buy | 15.47 | |
| Needham | 13 Nov 2024 | 22.00 (74.60%) | Buy | 12.02 |
| 12 Nov 2024 | 22.00 (74.60%) | Buy | 13.15 | |
| Oppenheimer | 31 Oct 2024 | 30.00 (138.10%) | Buy | 15.47 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| PALCZUK LINDA | - | 10.23 | -3,500 | -35,805 |
| Aggregate Net Quantity | -3,500 | |||
| Aggregate Net Value ($) | -35,805 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 10.23 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| PALCZUK LINDA | Director | 24 Dec 2024 | Disposed (-) | 3,500 | 10.23 | 35,805 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |